艾美疫苗(06660.HK)MDCK细胞流感疫苗获临床试验许可

阿斯达克财经
19 Dec 2024

艾美疫苗(06660.HK) 公布,集团新技术路线悬浮培养四价MDCK细胞流感疫苗,近日获得国家药品监督管局《药物临床试验批准通知书》,标志该疫苗的研发进入新阶段。MDCK细胞流感疫苗作为重磅大单品,该款产品上市后有望成为集团新的业绩增长点。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10